BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 25501132)

  • 1. CD99 triggering in Ewing sarcoma delivers a lethal signal through p53 pathway reactivation and cooperates with doxorubicin.
    Guerzoni C; Fiori V; Terracciano M; Manara MC; Moricoli D; Pasello M; Sciandra M; Nicoletti G; Gellini M; Dominici S; Chiodoni C; Fornasari PM; Lollini PL; Colombo MP; Picci P; Cianfriglia M; Magnani M; Scotlandi K
    Clin Cancer Res; 2015 Jan; 21(1):146-56. PubMed ID: 25501132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Engagement of CD99 Activates Distinct Programs in Ewing Sarcoma and Macrophages.
    Manara MC; Manferdini C; Cristalli C; Carrabotta M; Santi S; De Feo A; Caldoni G; Pasello M; Landuzzi L; Lollini PL; Salamanna F; Dominici S; Fiori V; Magnani M; Lisignoli G; Scotlandi K
    Cancer Immunol Res; 2024 Feb; 12(2):247-260. PubMed ID: 38051221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis and biological evaluation of Nucleosidic CD99 inhibitors that selectively reduce Ewing sarcoma viability.
    Balaraman K; Deniz E; Nelson E; Pilicer SL; Atasoy S; Molotkova A; Sevim H; Tiwari PB; Üren A; Wolf C
    Eur J Med Chem; 2023 May; 251():115244. PubMed ID: 36917882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-CD99 Antibody Therapy Triggers Macrophage-Dependent Ewing Cell Death In Vitro and Myeloid Cell Recruitment In Vivo.
    O'Neill AF; Nguyen EM; Maldonado ED; Chang MR; Sun J; Zhu Q; Marasco WA
    Antibodies (Basel); 2024 Mar; 13(1):. PubMed ID: 38534214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancing standard of care chemotherapy efficacy using DNA-dependent protein kinase (DNA-PK) inhibition in preclinical models of Ewing sarcoma.
    Collins VJ; Ludwig KR; Nelson AE; Sundara Rajan S; Yeung C; Vulikh K; Isanogle KA; Mendoza A; Difilippantonio S; Karim BO; Caplen NJ; Heske CM
    Mol Cancer Ther; 2024 Apr; ():. PubMed ID: 38657228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trabectedin efficacy in Ewing sarcoma is greatly increased by combination with anti-IGF signaling agents.
    Amaral AT; Garofalo C; Frapolli R; Manara MC; Mancarella C; Uboldi S; Di Giandomenico S; Ordóñez JL; Sevillano V; Malaguarnera R; Picci P; Hassan AB; De Alava E; D'Incalci M; Scotlandi K
    Clin Cancer Res; 2015 Mar; 21(6):1373-82. PubMed ID: 25609059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Process development of a human recombinant diabody expressed in E. coli: engagement of CD99-induced apoptosis for target therapy in Ewing's sarcoma.
    Moricoli D; Carbonella DC; Dominici S; Fiori V; Balducci MC; Guerzoni C; Manara MC; Pasello M; Laguardia ME; Cianfriglia M; Scotlandi K; Magnani M
    Appl Microbiol Biotechnol; 2016 May; 100(9):3949-63. PubMed ID: 26685854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD99 regulates neural differentiation of Ewing sarcoma cells through miR-34a-Notch-mediated control of NF-κB signaling.
    Ventura S; Aryee DN; Felicetti F; De Feo A; Mancarella C; Manara MC; Picci P; Colombo MP; Kovar H; Carè A; Scotlandi K
    Oncogene; 2016 Jul; 35(30):3944-54. PubMed ID: 26616853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ChIP-ping away at EWS/ETS transcription networks.
    Denny CT
    Cancer Cell; 2014 Nov; 26(5):595-6. PubMed ID: 25517742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD99 triggering induces methuosis of Ewing sarcoma cells through IGF-1R/RAS/Rac1 signaling.
    Manara MC; Terracciano M; Mancarella C; Sciandra M; Guerzoni C; Pasello M; Grilli A; Zini N; Picci P; Colombo MP; Morrione A; Scotlandi K
    Oncotarget; 2016 Nov; 7(48):79925-79942. PubMed ID: 27835596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic factors for survival in patients with Ewing's sarcoma using the surveillance, epidemiology, and end results (SEER) program database.
    Duchman KR; Gao Y; Miller BJ
    Cancer Epidemiol; 2015 Apr; 39(2):189-95. PubMed ID: 25595632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ewing sarcoma: a tough road to clinically relevant biomarkers.
    Shukla N
    Pediatr Blood Cancer; 2015 May; 62(5):741-2. PubMed ID: 25586427
    [No Abstract]   [Full Text] [Related]  

  • 13. Long-term Outcomes and Complications in Pediatric Ewing Sarcoma.
    Hamilton SN; Carlson R; Hasan H; Rassekh SR; Goddard K
    Am J Clin Oncol; 2017 Aug; 40(4):423-428. PubMed ID: 25599318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Developing a prognostic model for localized Ewing sarcoma family of tumors: A single institutional experience of 224 cases treated with uniform chemotherapy protocol.
    Biswas B; Rastogi S; Khan SA; Shukla NK; Deo SV; Agarwala S; Mohanti BK; Sharma MC; Vishnubhatla S; Bakhshi S
    J Surg Oncol; 2015 May; 111(6):683-9. PubMed ID: 25557999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Variable expression of PIK3R3 and PTEN in Ewing Sarcoma impacts oncogenic phenotypes.
    Niemeyer BF; Parrish JK; Spoelstra NS; Joyal T; Richer JK; Jedlicka P
    PLoS One; 2015; 10(1):e0116895. PubMed ID: 25603314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Post-relapse survival in patients with Ewing sarcoma.
    Ferrari S; Luksch R; Hall KS; Fagioli F; Prete A; Tamburini A; Tienghi A; DiGirolamo S; Paioli A; Abate ME; Podda M; Cammelli S; Eriksson M; Brach del Prever A
    Pediatr Blood Cancer; 2015 Jun; 62(6):994-9. PubMed ID: 25585917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD99 is a therapeutic target on disease stem cells in myeloid malignancies.
    Chung SS; Eng WS; Hu W; Khalaj M; Garrett-Bakelman FE; Tavakkoli M; Levine RL; Carroll M; Klimek VM; Melnick AM; Park CY
    Sci Transl Med; 2017 Jan; 9(374):. PubMed ID: 28123069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Significance of CD99 expression in T-lineage acute lymphoblastic leukemia.
    Enein AA; Rahman HA; Sharkawy NE; Elhamid SA; Abbas SM; Abdelfaatah R; Khalil M; Fathalla LA
    Cancer Biomark; 2016 Mar; 17(2):117-23. PubMed ID: 27002769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma.
    Perry JA; Kiezun A; Tonzi P; Van Allen EM; Carter SL; Baca SC; Cowley GS; Bhatt AS; Rheinbay E; Pedamallu CS; Helman E; Taylor-Weiner A; McKenna A; DeLuca DS; Lawrence MS; Ambrogio L; Sougnez C; Sivachenko A; Walensky LD; Wagle N; Mora J; de Torres C; Lavarino C; Dos Santos Aguiar S; Yunes JA; Brandalise SR; Mercado-Celis GE; Melendez-Zajgla J; Cárdenas-Cardós R; Velasco-Hidalgo L; Roberts CW; Garraway LA; Rodriguez-Galindo C; Gabriel SB; Lander ES; Golub TR; Orkin SH; Getz G; Janeway KA
    Proc Natl Acad Sci U S A; 2014 Dec; 111(51):E5564-73. PubMed ID: 25512523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Translating genomic discoveries to the clinic in pediatric oncology.
    Glade Bender J; Verma A; Schiffman JD
    Curr Opin Pediatr; 2015 Feb; 27(1):34-43. PubMed ID: 25502895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.